Page last updated: 2024-08-23

ethylketocyclazocine and Carcinoma, Anaplastic

ethylketocyclazocine has been researched along with Carcinoma, Anaplastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alexaki, VI; Castanas, E; Hatzoglou, A; Kampa, M; Papakonstanti, EA; Stournaras, C	1

Other Studies

1 other study(ies) available for ethylketocyclazocine and Carcinoma, Anaplastic

Article	Year
The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line. Experimental cell research, 2004, Apr-01, Volume: 294, Issue:2 Topics: Actin Cytoskeleton; Analgesics, Opioid; Binding Sites; Binding, Competitive; Carcinoma; Cell Division; Cell Membrane; Ethylketocyclazocine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Opioid Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Reaction Time; Receptors, Androgen; Serum Albumin, Bovine; Signal Transduction; Testosterone; Tumor Cells, Cultured	2004

Article

Year

The opioid agonist ethylketocyclazocine reverts the rapid, non-genomic effects of membrane testosterone receptors in the human prostate LNCaP cell line.

Experimental cell research, 2004, Apr-01, Volume: 294, Issue:2

Topics: Actin Cytoskeleton; Analgesics, Opioid; Binding Sites; Binding, Competitive; Carcinoma; Cell Division; Cell Membrane; Ethylketocyclazocine; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Male; Opioid Peptides; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Reaction Time; Receptors, Androgen; Serum Albumin, Bovine; Signal Transduction; Testosterone; Tumor Cells, Cultured

2004